Therapeutic Research

Volume 37, Issue 9, 2016
Volumes & issues:
-
Topics:「臨床研究と疫学研究のための国際ルール集Part 2」刊行によせて①
-
-
-
INFORMATION:日本循環器学会 第20回プレスセミナー 循環器画像診断の進歩
-
-
-
Symposium:日本循環器学会,日本サルコペニア・フレイル研究会 ジョイントシンポジウム 循環器疾患とサルコペニアを考える
-
-
-
-
3.サルコペニア合併心疾患患者に対する心臓リハビリテーション:レジスタンストレーニング併用の効果と重症度の影響
37巻9号(2016);View Description
Hide Description
-
-
-
-
Symposium:第48回埼玉不整脈ペーシング研究会
-
- 一般演題
-
-
3D画像ワークステーションを併用した心房細動アブレーションの3D mapping systemにおける左房抽出方法の検討
37巻9号(2016);View Description
Hide Description
-
-
-
-
原著
-
-
Febuxostat Prevents Renal Function Decline in Hyperuricemic Patients
37巻9号(2016);View Description
Hide Description
Twenty patients with hyperuricemia were administered febuxostat to prevent renal function decline by lowering uric acid. Patients consisted of 17 males and 3 females having age of 72±9 y(mean±SD). Patients had hyperuricemia with chronic kidney disease (CKD)of various causes. After receiving febuxostat 20 mg daily, their serum uric acid decreased from 8.0±2.5 to 5.9±1.0 mg/dL, serum creatinine from 1.34±0.29 to 1.18±0.24 mg/dL, and estimated glomerular filtration rate(eGFR) recovered from 41.2±9.9 to 46.9±11.7 mL/min. Observed values were statistically significant(Student paired t‒test, p<0.01). No new gout attacks were observed under febuxostat stepwise loading. In conclusion, febuxostat is a safe and effective agent to decrease serum uric acid levels under 6.0 mg/dL. Furthermore, after receiving febuxostat, improved renal function was exhibited by all twenty CKD patients with hyperuricemia. -
Gastric Emptying in Idiopathic Pulmonary Fibrosis Patients Treated with Pirfenidone
37巻9号(2016);View Description
Hide Description
Idiopathic pulmonary fibrosis(IPF)is a chronic, progressive fibrosing interstitial pneumonia of unknown etiology with a poor prognosis. Pirfenidone(PFD)is an antifibrotic agent that is used to treat IPF patients, but gastrointestinal(GI)adverse events are common. This study investigated whether impaired gastric emptying was the underlying cause of GI adverse events in patients receiving PFD. Gastric emptying was assessed by the continuous 13C breath test before and after one month PFD therapy, and GI symptoms were assessed by using the modified Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease(MFSSG) questionnaire on IPF patients. The MFSSG score increased after PFD therapy, but gastric emptying was not significantly affected in the calculated parameters, gastric emptying coefficient(GEC), the analog to the scintigraphy lag time for 10% emptying labeled meal(Tlag)and half excretion time(T1/2)at a dose of 1200 mg/day. Gastric emptying of IPF patients was not significantly affected by PFD at 1200 mg/day and GI symptoms were tolerable at that dose.
-
-
INFORMATION
-
-